{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:26:23Z","timestamp":1790670383777,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract\u00a0\u00a0<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Depression is a prodromic and a frequent non-motor symptom of Parkinson\u2019s disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson\u2019s disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and conclusion<\/jats:title><jats:p>Experts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients\u2019 characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10072-023-06740-w","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:02:12Z","timestamp":1682553732000},"page":"3123-3131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring depression in Parkinson\u2019s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-0033","authenticated-orcid":false,"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"family":"Angelo Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferini Strambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"6740_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"2","author":"JS Reijnders","year":"2008","unstructured":"Reijnders JS, Ehrt U, Weber WE et al (2008) A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord 2:183\u2013189. https:\/\/doi.org\/10.1002\/mds.21803","journal-title":"Mov Disord"},{"key":"6740_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/gps.4350","volume":"31","author":"GM Pontone","year":"2016","unstructured":"Pontone GM, Bakker CC, Chen S et al (2016) The longitudinal impact of depression on disability in Parkinson disease. Int J Geriatr Psychiatry 31:458\u2013465. https:\/\/doi.org\/10.1002\/gps.4350","journal-title":"Int J Geriatr Psychiatry"},{"key":"6740_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson\u2019s disease. Mov Disord 34:1464\u20131470. https:\/\/doi.org\/10.1002\/mds.27802","journal-title":"Mov Disord"},{"key":"6740_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pnpbp.2018.05.025","volume":"86","author":"S Wang","year":"2018","unstructured":"Wang S, Mao S, Xiang D, Fang C (2018) Association between depression and the subsequent risk of Parkinson\u2019s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 86:186\u2013192. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.05.025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"6740_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","volume":"277","author":"M Politis","year":"2015","unstructured":"Politis M, Niccolini F (2015) Serotonin in Parkinson\u2019s disease. Behav Brain Res. 277:136\u2013145. https:\/\/doi.org\/10.1016\/j.bbr.2014.07.037","journal-title":"Behav Brain Res."},{"issue":"7","key":"6740_CR6","doi-asserted-by":"publisher","first-page":"e0131133","DOI":"10.1371\/journal.pone.0131133","volume":"10","author":"X Hu","year":"2015","unstructured":"Hu X, Song X, Li E et al (2015) Altered resting-state brain activity and connectivity in depressed Parkinson\u2019s disease. PLoS One. 10(7):e0131133. https:\/\/doi.org\/10.1371\/journal.pone.0131133","journal-title":"PLoS One."},{"issue":"1","key":"6740_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002512-199812010-00006","volume":"12","author":"T Tom","year":"1998","unstructured":"Tom T, Cummings JL (1998) Depression in Parkinson\u2019s disease. Pharmacological characteristics and treatment. Drugs Aging. 12(1):55\u201374. https:\/\/doi.org\/10.2165\/00002512-199812010-00006","journal-title":"Pharmacological characteristics and treatment. Drugs Aging."},{"key":"6740_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.69864\/ijbsam.9-2.106","volume":"9","author":"L Giannarou","year":"2014","unstructured":"Giannarou L, Zervas E (2014) Using Delphi technique to build consensus in practice. Int J Bus Sci Appl Manage 9:65\u201382","journal-title":"Int J Bus Sci Appl Manage"},{"issue":"8","key":"6740_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-015-1370-z","volume":"122","author":"D Frosini","year":"2015","unstructured":"Frosini D, Unti E, Guidoccio F et al (2015) Mesolimbic dopaminergic dysfunction in Parkinson\u2019s disease depression: evidence from a 123I-FP-CIT SPECT investigation. J Neural Transm (Vienna) 122(8):1143\u20131147. https:\/\/doi.org\/10.1007\/s00702-015-1370-z","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"6740_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2741\/S518","volume":"10","author":"MS Gold","year":"2018","unstructured":"Gold MS, Blum K, Febo M et al (2018) Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. Front Biosci (Schol Ed) 10(2):309\u2013325. https:\/\/doi.org\/10.2741\/S518","journal-title":"Front Biosci (Schol Ed)"},{"issue":"10","key":"6740_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11910-017-0788-0","volume":"17","author":"S Thobois","year":"2017","unstructured":"Thobois S, Prange S, Sgambato-Faure V, Tremblay L, Broussolle E (2017) Imaging the etiology of apathy, anxiety, and depression in Parkinson\u2019s disease: implication for treatment. Curr Neurol Neurosci Rep 17(10):76. https:\/\/doi.org\/10.1007\/s11910-017-0788-0","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Pt 9","key":"6740_CR12","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet A, Krack P, Lhomm\u00e9e E et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain 139(Pt 9):2486\u20132502. https:\/\/doi.org\/10.1093\/brain\/aww162","journal-title":"Brain"},{"issue":"Pt 6","key":"6740_CR13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314\u20131322. https:\/\/doi.org\/10.1093\/brain\/awh445","journal-title":"Brain"},{"issue":"4","key":"6740_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1176\/appi.neuropsych.11110332","volume":"24","author":"G Loas","year":"2012","unstructured":"Loas G, Krystkowiak P, Godefroy O (2012) Anhedonia in Parkinson\u2019s disease: an overview. J Neuropsychiatry Clin Neurosci. 24(4):444\u201351. https:\/\/doi.org\/10.1176\/appi.neuropsych.11110332","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"6740_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J Neurol Sci 248:266\u2013270. https:\/\/doi.org\/10.1016\/j.jns.2006.05.024","journal-title":"J Neurol Sci"},{"issue":"5","key":"6740_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","volume":"75","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Mavandadi S, Mamikonyan E et al (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75(5):448\u2013455. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ebdd79","journal-title":"Neurology"},{"issue":"6","key":"6740_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2174\/1871527318666190703093345","volume":"18","author":"I Berardelli","year":"2019","unstructured":"Berardelli I, Belvisi D, Nardella A et al (2019) Suicide in Parkinson\u2019s disease: a systematic review. CNS Neurol Disord Drug Targets 18(6):466\u2013477. https:\/\/doi.org\/10.2174\/1871527318666190703093345","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"7","key":"6740_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/jnnp-2018-319815","volume":"90","author":"MD Shepard","year":"2019","unstructured":"Shepard MD, Perepezko K, Broen MPG et al (2019) Suicide in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 90(7):822\u2013829. https:\/\/doi.org\/10.1136\/jnnp-2018-319815","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"6740_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1474-4422(18)30044-9","volume":"17","author":"A Antonini","year":"2018","unstructured":"Antonini A, Obeso JA (2018) DBS for Parkinson\u2019s disease with behavioural disturbances. Lancet Neurol 17(3):195\u2013197. https:\/\/doi.org\/10.1016\/S1474-4422(18)30044-9","journal-title":"Lancet Neurol"},{"key":"6740_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-022-11269-7","volume":"25","author":"F Garr\u00ec","year":"2022","unstructured":"Garr\u00ec F, Russo FP, Carrer T et al (2022) Long-term safety, discontinuation, and mortality in an Italian cohort with advanced Parkinson\u2019s disease on levodopa\/carbidopa intestinal gel infusion. J Neurol 25:1\u20139. https:\/\/doi.org\/10.1007\/s00415-022-11269-7","journal-title":"J Neurol"},{"issue":"283","key":"6740_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jad.2021.01.056","volume":"15","author":"YE Chan","year":"2021","unstructured":"Chan YE, Chen MH, Bai YM, Li CT, Chen TJ, Su TP (2021) Treatment response and age of onset as risk indicators for Parkinson disease in patients with major depressive disorder: a nationwide longitudinal study. J Affect Disord 15(283):329\u2013334. https:\/\/doi.org\/10.1016\/j.jad.2021.01.056","journal-title":"J Affect Disord"},{"issue":"2","key":"6740_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1176\/jnp.13.2.187","volume":"13","author":"JR Slaughter","year":"2001","unstructured":"Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 13(2):187\u201396. https:\/\/doi.org\/10.1176\/jnp.13.2.187","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"6740_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0033-3182(98)71300-3","volume":"39","author":"WJ Hoogendijk","year":"1998","unstructured":"Hoogendijk WJ, Sommer IE, Tissingh G, Deeg DJ, Wolters EC (1998) Depression in Parkinson\u2019s disease. The impact of symptom overlap on prevalence. Psychosomatics 39(5):416\u2013421. https:\/\/doi.org\/10.1016\/S0033-3182(98)71300-3","journal-title":"Psychosomatics"},{"issue":"1","key":"6740_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","volume":"35","author":"C Baiano","year":"2020","unstructured":"Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment (MCI) in Parkinson\u2019s disease: a meta-analysis. Mov Disord 35(1):45\u201354. https:\/\/doi.org\/10.1002\/mds.27902","journal-title":"Mov Disord"},{"issue":"19","key":"6740_CR25","doi-asserted-by":"publisher","first-page":"30215","DOI":"10.1016\/j.parkreldis.2019.04.020","volume":"S1353\u20138020","author":"D Saredakis","year":"2019","unstructured":"Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD (2019) Conversion to MCI and dementia in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord S1353\u20138020(19):30215\u201330219. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.04.020","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"6740_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s007020050005","volume":"107","author":"N Giladi","year":"2000","unstructured":"Giladi N, Treves TA, Paleacu D et al (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson\u2019s disease. J Neural Transm 107(1):59\u201371. https:\/\/doi.org\/10.1007\/s007020050005","journal-title":"J Neural Transm"},{"issue":"184","key":"6740_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jad.2015.05.059","volume":"15","author":"E Torbey","year":"2015","unstructured":"Torbey E, Pachana NA, Dissanayaka NN (2015) Depression rating scales in Parkinson\u2019s disease: a critical review updating recent literature. J Affect Disord 15(184):216\u2013224. https:\/\/doi.org\/10.1016\/j.jad.2015.05.059","journal-title":"J Affect Disord"},{"key":"6740_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/mds.20723","volume":"21","author":"L Marsh","year":"2006","unstructured":"Marsh L, McDonald WM, Cummings J, Ravina B (2006) Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH work group. Mov Disord 21:148\u2013158. https:\/\/doi.org\/10.1002\/mds.20723","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"6740_CR29","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M et al (2011) The Movement Disorder Society evidence-based Medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. MovDisord 26(Suppl 3):S42-80. https:\/\/doi.org\/10.1002\/mds.23884","journal-title":"MovDisord"},{"issue":"9","key":"6740_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800\u2013809. https:\/\/doi.org\/10.1212\/WNL.0b013e318285c0ed","journal-title":"Neurology"},{"key":"6740_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","volume":"14","author":"WG Ondo","year":"2008","unstructured":"Ondo WG, Lai D (2008) Predictors of impulsivity and reward seeking behaviour with dopamine agonists. Parkinsonism Relat Disord 14:28\u201332. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.05.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"6740_CR32","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/gps.4834","volume":"33","author":"KA Mills","year":"2018","unstructured":"Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM (2018) Efficacy and tolerability of antidepressants in Parkinson\u2019s disease: a systematic review and network meta-analysis. Int J Geriatr Psychiatry 33(4):642\u2013651. https:\/\/doi.org\/10.1002\/gps.4834","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"6740_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00228-020-02847-7","volume":"76","author":"AD Dunvald","year":"2020","unstructured":"Dunvald AD, Henriksen DP, Hallas J, Christensen MMH, Lund LC (2020) Selective serotonin reuptake inhibitors and the risk of restless legs syndrome: a symmetry analysis. Eur J Clin Pharmacol 76(5):719\u2013722. https:\/\/doi.org\/10.1007\/s00228-020-02847-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"6740_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","volume":"20","author":"A Revet","year":"2020","unstructured":"Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH (2020) Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 20(1):308. https:\/\/doi.org\/10.1186\/s12888-020-02711-z","journal-title":"BMC Psychiatry"},{"issue":"10","key":"6740_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/1060028015594812","volume":"49","author":"JM Hawthorne","year":"2015","unstructured":"Hawthorne JM, Caley CF (2015) Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 49(10):1136\u20131152. https:\/\/doi.org\/10.1177\/1060028015594812","journal-title":"Ann Pharmacother"},{"key":"6740_CR36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/phar.1500","volume":"34","author":"M Panisset","year":"2014","unstructured":"Panisset M, Chen JJ, Rhyee SH et al (2014) Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy 34:1250\u20131258. https:\/\/doi.org\/10.1002\/phar.1500","journal-title":"Pharmacotherapy"},{"issue":"6","key":"6740_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jagp.2021.02.037","volume":"29","author":"GM Pontone","year":"2021","unstructured":"Pontone GM, Mills KA (2021) Optimal treatment of depression and anxiety in Parkinson\u2019s disease. Am J Geriatr Psychiatry 29(6):530\u2013540. https:\/\/doi.org\/10.1016\/j.jagp.2021.02.037","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"6740_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/mds.20895","volume":"21","author":"A Antonini","year":"2006","unstructured":"Antonini A, Tesei S, Zecchinelli A et al (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson\u2019s disease and depression: effect on quality of life. Mov Disord 21(8):1119\u20131122. https:\/\/doi.org\/10.1002\/mds.20895","journal-title":"Mov Disord"},{"issue":"1","key":"6740_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","volume":"14","author":"X Gonda","year":"2019","unstructured":"Gonda X, Sharma SR, Tarazi FI (2019) Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov 14(1):81\u201389. https:\/\/doi.org\/10.1080\/17460441.2019.1546691","journal-title":"Expert Opin Drug Discov"},{"issue":"17","key":"6740_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/NDT.S296451","volume":"22","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Loft H, Christensen MC (2021) Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder. Neuropsychiatr Dis Treat 22(17):575\u2013585. https:\/\/doi.org\/10.2147\/NDT.S296451","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6740_CR41","doi-asserted-by":"publisher","first-page":"204512532110267","DOI":"10.1177\/20451253211026796","volume":"11","author":"MM Bishop","year":"2021","unstructured":"Bishop MM, Fixen DR, Linnebur SA, Pearson SM (2021) Cognitive effects of vortioxetine in older adults: a systematic review. Ther Adv Psychopharmacol 11:20451253211026796. https:\/\/doi.org\/10.1177\/20451253211026796","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06740-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06740-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06740-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T08:00:56Z","timestamp":1729324856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06740-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6740"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06740-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"18 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our manuscript does not report on or involve the use of any animal or human data or tissue and does not contain data from any individual person, so this section is not applicable to our submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"F. B. has received compensation for consultancy and speaker related activities from Zambon, UCB, Chiesi Pharma, Lundbeck, Sunovion, Bial, SynAgile, Biogen, Kiowa, and Impax. A. A. has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche, and Medscape; he receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grant 825785, Horizon 2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, and Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling. A. F. is\/has been a consultant and\/or a speaker and\/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Lundbeck, Janssen, Viatris, Otsuka, Recordati, Sanofi-Aventis, and Sunovion. LFS has received speaker fees from Jazz Pharma, Lundbeck, Angelini, Valeas, Bioprojet, Fidia, and Idorsia and has served on scientific advisory boards for Jazz Pharma, Italfarmaco, Bioprojet, Bayer, and Idorsia. C. M. received funds from the following companies: Novo-nordisk, Angelini, Lundbeck, Roche, and Biogen as consultant in scientific board and congress speaker. P. B., G. B., S. S., and A. P. declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}